Bio-Rad Remedi HS sales could double following FDA clearance, firm tells analysts.
This article was originally published in The Gray Sheet
Executive Summary
BIO-RAD REMEDI HS DRUG PROFILING SYSTEM annual unit sales of 20-25 could double following FDA's recent clearance of a 510(k) for the product, James Bennett, Bio-Rad's chief operating officer, told analysts May 23 in New York City. The Remedi HS, which sells for about $100,000, was cleared by the agency in March. Since its introduction in 1990, Bio-Rad has placed about 150 of the systems with international customers and in U.S. hospitals that are using the system on an investigational basis.